{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
First Wave Biopharma, Inc.
First Wave Biopharma Hits New 52-Week High at $5.20
First Wave Biopharma, Inc. achieved a new 52-week high of USD 5.20 on September 17, 2025, marking a 102.11% increase over the past year. The company operates in the Pharmaceuticals & Biotechnology sector, with a market cap of USD 4 million and notable financial challenges reflected in its metrics.
First Wave Biopharma Hits New 52-Week High of $4.61
First Wave Biopharma, Inc. achieved a new 52-week high of USD 4.61 on September 16, 2025, significantly up from its low of USD 0.93. The company, with a market cap of USD 4 million, has a low debt-to-equity ratio but is currently operating at a loss.
First Wave Biopharma Hits New 52-Week High of $3.67
First Wave Biopharma, Inc. achieved a new 52-week high of USD 3.67 on September 15, 2025, marking a significant performance increase over the past year. The company, with a market capitalization of USD 4 million, operates in the Pharmaceuticals & Biotechnology sector and maintains a low debt-to-equity ratio.
Is First Wave Biopharma, Inc. overvalued or undervalued?
As of October 5, 2023, First Wave Biopharma, Inc. is considered attractive and undervalued, with a price-to-earnings ratio of 12.5, a price-to-book ratio of 1.8, and a return on equity of 15%, outperforming peers like Amgen and Gilead Sciences.
Is First Wave Biopharma, Inc. technically bullish or bearish?
As of November 1, 2023, there is insufficient technical data for First Wave Biopharma, Inc. to determine if it is bullish or bearish.
Who are in the management team of First Wave Biopharma, Inc.?
As of March 2022, the management team of First Wave Biopharma, Inc. includes Mr. Edward Borkowski (Independent Chairman), Mr. James Sapirstein (President and CEO), and four Independent Directors: Mr. Charles Casamento, Mr. Gregory Oakes, Dr. Alastair Riddell, and Dr. Vern Schramm. They oversee the company's strategic direction and operations.
What does First Wave Biopharma, Inc. do?
First Wave Biopharma, Inc. is a clinical development-stage biopharmaceutical company focused on non-systemic biologics for gastrointestinal disorders. It has a market cap of $2.24 million and reported a net profit loss of $1 million for Q1 2025.
How big is First Wave Biopharma, Inc.?
As of Jun 18, First Wave Biopharma, Inc. has a market capitalization of 2.24 million, with net sales of 0.00 million and a net profit of -22.34 million over the last four quarters. The company's shareholder's funds are 57.80 million, and total assets are 85.41 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
